Agios Pharmaceuticals (AGIO) Q4 2025 earnings summary

Executive summary

• Achieved strong commercial execution in Q4 and FY 2025, with significant revenue growth and successful launches in rare hematology, including FDA approval and US launch of ACTIVASE/AQVESME (mitapivat) for thalassemia.

• Advanced pipeline with key milestones: completed enrollment in phase II tebapivat sickle cell trial, pre-sNDA meeting for mitapivat in sickle cell disease, and early-stage pipeline progress for AG-181 and AG-236.

• Maintained robust financial discipline, ending 2025 with $1.2B in cash, supporting flexibility for launches and pipeline advancement.

• Clear path to profitability based on thalassemia and PK deficiency franchises, with disciplined capital allocation and operational efficiency.

Financial highlights

• Q4 2025 PYRUKYND net revenue: $20M, up 86% year-over-year and 55% sequentially; FY 2025 net revenue: $54M, up 48% from FY 2024.

• U.S. Q4 PYRUKYND revenue: $16M; ex-U.S. Q4 revenue: $4M, mainly from European inventory stocking.

• FY 2025 net loss was $(412.8)M, compared to net income of $673.7M in FY 2024, which included significant one-time gains.

• Q4 cost of sales: $1.9M; R&D expenses: $88.1M (up YoY); SG&A: $51.6M (flat YoY).

• Cash, cash equivalents, and marketable securities at year-end: $1.2B.

Outlook and guidance

• 2026 US PK deficiency revenue expected at $45–$50M.

• Operating expenses in 2026 anticipated to be roughly flat with 2025, with investments focused on ACTIVASE/AQVESME launch and pipeline.

• Anticipate strong catalyst flow in 2026, including regulatory milestones and topline data readouts for multiple pipeline assets.

• Ex-US revenue expected to decline sequentially in Q1 2026 due to inventory dynamics.

• Clear path to profitability through thalassemia and PK deficiency commercial presence.